Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)

INTRODUCTION: Imeglimin is a novel anti-hyperglycemic drug that improves both insulin resistance and insulin secretion. The effects of imeglimin on glycemic control were confirmed in phase III clinical trials, but little is known about its effectiveness in daily clinical practice settings, especiall...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomoto, Hiroshi, Takahashi, Akihiro, Nakamura, Akinobu, Kurihara, Hiroyoshi, Takeuchi, Jun, Nagai, So, Taneda, Shinji, Miya, Aika, Kameda, Hiraku, Cho, Kyu Yong, Miyoshi, Hideaki, Atsumi, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667996/
https://www.ncbi.nlm.nih.gov/pubmed/36379585
http://dx.doi.org/10.1136/bmjdrc-2022-002988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667996/
https://www.ncbi.nlm.nih.gov/pubmed/36379585
http://dx.doi.org/10.1136/bmjdrc-2022-002988

Ejemplares similares